The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Nonfasting Remnant Cholesterol in a Real World Population

Table 2

Lipid levels before and after treatment.

	Pre-treatment	Post-treatment	Change	P value
Total cholesterol	259.6 ± 70.1	151.5 ± 52.7	–41%	<0.001
HDLc	45.1 ± 11.3	46.0 ± 11.8	2%	0.228
NonHDLc	215.1 ± 68.6	106.5 ± 52.4	–50%	<0.001
Triglycerides	255.3 ± 161.7	191.9 ± 99.8	–24%	<0.001
LDLc
Friedewald equation	167.0 ± 57.2	70.11 ± 47.2	–58%	<0.001
Direct measurement	174.5 ± 57.2	76.9 ± 46.4	–56%	<0.001
Martin/Hopkins method	171.3 ± 56.4	76.9 ± 46.0	–55%	<0.001
Remnant cholesterol
Friedewald equation LDLc	48.1 ± 28.2	36.4 ± 16.5	–24%	<0.001
Direct measurement LDLc	40.6 ± 29.9	29.6 ± 15.4	–27%	<0.001
Martin/Hopkins method LDLc	43.8 ± 27.2	29.6 ± 13.1	–32%	<0.001
Apolipoprotein B (n = 98)	141.4 ± 40.8	74.2 ± 30.5	–48%	<0.001

HDLc = high density lipoprotein cholesterol, LDLc = low density lipoprotein cholesterol.